We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.875 | 9.50 | 10.25 | 9.875 | 9.875 | 9.88 | 326,679 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.65 | 91.58M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/7/2018 09:56 | "And I’ll say it early—I have a slide at the end. My impression and other colleagues’ is that we’re now not looking to do huge trials with hundreds of patients. We’re looking to initially, cautiously move forward and look at these combinations, either early or in patients who are PD-1 relapsers or refractory and find that exquisite responder." Omid Hamid | gooosed | |
28/7/2018 06:34 | Change the tt in https to capitals - so make it hTTps | bermudashorts | |
28/7/2018 02:17 | Any tips Guys on avoiding this link problem ? Thanks. | torquayfan | |
28/7/2018 02:15 | ''Merck & Co’s cancer immunotherapy Keytruda has finally overtaken Bristol-Myers Squibb’s rival Opdivo in sales – and EU regulators just rejected a new use for BMS’ drug while green-lighting two new indications for its competitor'' and ''Sales of Keytruda rose 89.2% compared with last year’s Q2 to $1.67 billion''. Can extrapolate from that 89% increase - maybe Keytruda sales this year will increase to $7-8 billion a year or more. Next year who knows ? That's a lotta dolla ! And Scancell are soon to be part of the Keytruda picture . . | torquayfan | |
27/7/2018 20:19 | Dr back in here for a trade only 6k but will get more free shares soon. | thelogman | |
27/7/2018 20:07 | Tel me tell me Loggie what you mean by 8 days. I am as giddy as A Goat about buying low and selling High ans as ECited as vaNANA in never never £6 a share lsnd | drdobson1 | |
27/7/2018 19:39 | Only 8 days left to start making money, anyone else waiting with excitement. | thelogman | |
27/7/2018 16:28 | Lozan, here we are another month gone and still no IND submitted for a trial we were told would commence in 2017, what an absolute shambles, perhaps they need to get a professional in to complete the form for them. | panama7 | |
27/7/2018 16:25 | Lozan, not sure you are aware of my circumstances I have never bought shares in Scancell at anywhere near 34p or above. The point is any CEO of any company that makes a statement as Goodfellow did 5.5 years ago and leaves Investors out of pocket ever since is a pretty reprehensible individual. He has shown arrogance, contempt and utter disdain for Investors and their money. He has not once apologised, taken responsibility or acknowledged his irresponsibility. Only someone with no integrity, morals, ethics or honesty would act in such a way. When Tosh asked him at that presentation about funding listen to the contemptuous way in which he responded. It is obvious people like him see PI's as nothing more than an inconvenience to be milked when it suits the Company. | panama7 | |
27/7/2018 13:48 | Just another 'Alternative View' - In the past year or so, WHAT, if anything has emerged / changed... on the 'science front'... that wasn't known / planned / needed trials to PROVE-UP... before ??? WHY wasn't SCLP 'in-the-running' to be a candidate for previous CRUK awards ??? *WE ALL* were told "Doors were OPEN"... BUT, it appears 'NO ONE was at home' in regards to the idea of a "GET SCANCELL" scenario. When the subject of 'reluctance of BIG PHARMA / DEALS' to become a REALITY ... DID the 'route to NECESSARY FUNDS' ONLY THEN become an 'option' ??? WHY is the CRUK 'option' ...'Top-of-the-Pops' If folks 'get my drift' ??? | the real lozan | |
27/7/2018 12:57 | Yes great to see Balance posting on here and MAYbe WE AlL have a better understanding of WHY people DO NOT want to buy at these Leveks. Mainly DOWN to trHYPER# as Loz says who SCAM SCAM t much higher prices like 22 and 34p on PROmises of £6 a share. These are folk who should hang head in shameJust Pity the pri e has to drop to these owls before WEALl agree with NOW is not a bad time to CONside buying | drdobson1 | |
27/7/2018 12:00 | Tick Tock? Let's hope it doesn't stop after 90 years! | gazza | |
27/7/2018 10:49 | P 7 - I am /was AWARE of your 'circumstances'... and have deliberately avoided 'straying into that area' ...I DO = "spare a thought for those Investors that bought at over 34p 5 years ago that have never got their money back." I actually think there are MANY " Investors that bought at over 34p 5 years ago that have never got their money back." IN FACT,Only a few days ago, I mentioned 'The MANY MULTIPLES' topic / LESSON, that some would 'prefer that topic / LESSON, was LOST in the mists of time'. The same 'gang' who use 'mind games' language, to promote the BUY,BUY,BUY, by introducing / inventing the subliminal term ="GET SCANCELL" It seems 'popular' to disregard my Alternative Views ...EVEN WHEN, those 'Alternative Views' are SHOWN to have 'paid-off'. { When trHYPE = HASN'T} | the real lozan | |
27/7/2018 09:21 | Lozan , with regards to Investors at 19p getting their money back, spare a thought for those Investors that bought at over 34p 5 years ago that have never got their money back. Not once has Goodfellow help his hand up, apologised or taken any responsibility, what a truly despicable man he is. As for "GET SCANCELL" one has to wonder if Goodfellow could have sold the Company for many multiples of 34p five years ago to numerous significantly interested Companies, why has not one of these Companies consummated one single deal in the last 5 years. Why has SCIB1 been sat on a shelf for 5 years with absolutely no interest shown. Why is the trial being continually delayed, why are we as Investors being continually fobbed off and misled. | panama7 | |
27/7/2018 09:15 | Nice to see balanced individuals making balanced posts, contributing to a balanced BB and an understanding of the risk/reward balance. | gazza | |
27/7/2018 09:13 | Hi ONW. I think I follow that. Patience then. Tick tock as Inan would say ATB | torquayfan | |
27/7/2018 09:03 | TF Not often that I've recently replied directly to one of your posts but when you say, "Myself I only grasp a modicum about Scancell science - but IF I was BIG Pharma - I'd be saying - GET SCANCELL !!" Since Scancell haven't been "got" and (we) as the oft declared not particularly science oriented keep thinking that the company must be being watched by Big Pharma, what's the reason we've received no approach.... UNLESS those who are Science savvy (ie Big Pharma) have decided ('til now at least) it's too early to commit. As you've stated that you amongst many who aren't in the "Science know all group" have been expecting some sort of Takeover/ interest, are those who've been saying since 2012 we'll be snapped up (or at least see a significant share price rise on the back of outside interest) equally as naive in terms of Scancell's commercialisation (whilst knowing all the science apparently) because they seem to be equally as wrong in their predictions for the share price as we in our predictions for the effects of the (significantly) improving science. Merely a thought, but one that your sentence quoted above prompted me to think about. AIMO ATB | oldnotwise | |
27/7/2018 08:34 | I should add, this is presumably why the chairman, who likely does have a better angle on BP interest and the balance of risk/reward, has recently (nigh on) doubled his position here. | wigwammer | |
27/7/2018 08:23 | Gazza - thanks for a balanced post. I see your point to a degree - they have not SAID Get Scancell - but that doesn't mean they are not SAYING Get Scancell. We don't know when news may arrive. As with all stocks - it is the news which is not predicted which is most impactful - otherwise, it would already be "in the price". Clearly, investors need to take a balanced view of risk and reward. My view is - with the shares near the lows again and with a large funding recently under their belt, the balance has shifted in favour of buying again. They have a decent cash runway, milestones within sight, the potential for left field surprises, and room within the valuation for a positive rerate. | wigwammer | |
27/7/2018 07:19 | TFYes, BP are pursuing the lines they believe will bring the best result quickest and possibly cheapest. I guess our hope is that our trial results will be so compelling that we can no longer be ignored. This will take time imo. | gazza | |
27/7/2018 01:05 | Gazza - you ask a good question - I really don't know. My pet theory is that most BP Exec's have committed to a line of research with massive funds and their own reputation and career is so vested ? Of course all Big Pharma will have Teams 'looking around' but do they have the level of understanding and clout needed ? Really if just one BP was really devoted to Scancell's ideas, SO much resource could be put forward as to be able to blast any thoughts of Scancell retaining the IP right out of the sky. On the other hand, as wigw posted, ''the positive news events earlier in the year were predicted by no one''. And the train of science stands up to 'Patent' examination. Hard to finger why this is sub 12 pence. GET SCANCELL ! (One for the 'gang of four' to 'larrup'). ATB | torquayfan |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions